Estimates of Presumed Population Immunity to SARS-CoV-2 by State in the United States, August 2021

被引:3
|
作者
Stoner, Marie C. D. [1 ]
Angulo, Frederick J. [2 ]
Rhea, Sarah [1 ,3 ]
Brown, Linda Morris [1 ]
Atwell, Jessica E. [2 ]
Nguyen, Jennifer L. [2 ]
McLaughlin, John M. [2 ]
Swerdlow, David L. [2 ]
MacDonald, Pia D. M. [1 ,4 ]
机构
[1] RTI Int, Res Triangle Pk, NC USA
[2] Pfizer Inc, Pfizer Vaccines, Med Dev Sci & Clin Affairs, Collegeville, PA USA
[3] North Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Raleigh, NC USA
[4] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2022年 / 9卷 / 02期
关键词
COVID-19; vaccination; population immunity; SARS-CoV-2; NONMEDICAL VACCINE EXEMPTIONS; COVID-19; VACCINE; PERTUSSIS;
D O I
10.1093/ofid/ofab647
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Information is needed to monitor progress toward a level of population immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sufficient to disrupt viral transmission. We estimated the percentage of the US population with presumed immunity to SARS-CoV-2 due to vaccination, natural infection, or both as of August 26, 2021. Methods Publicly available data as of August 26, 2021, from the Centers for Disease Control and Prevention were used to calculate presumed population immunity by state. Seroprevalence data were used to estimate the percentage of the population previously infected with SARS-CoV-2, with adjustments for underreporting. Vaccination coverage data for both fully and partially vaccinated persons were used to calculate presumed immunity from vaccination. Finally, we estimated the percentage of the total population in each state with presumed immunity to SARS-CoV-2, with a sensitivity analysis to account for waning immunity, and compared these estimates with a range of population immunity thresholds. Results In our main analysis, which was the most optimistic scenario, presumed population immunity varied among states (43.1% to 70.6%), with 19 states with <= 60% of their population having been infected or vaccinated. Four states had presumed immunity greater than thresholds estimated to be sufficient to disrupt transmission of less infectious variants (67%), and none were greater than the threshold estimated for more infectious variants (>= 78%). Conclusions The United States remains a distance below the threshold sufficient to disrupt viral transmission, with some states remarkably low. As more infectious variants emerge, it is critical that vaccination efforts intensify across all states and ages for which the vaccines are approved.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] SARS-CoV-2 herd immunity of the Kyrgyz population in 2021
    Anna Y. Popova
    Omor T. Kasymov
    Vyacheslav Y. Smolenski
    Vyacheslav S. Smirnov
    Svetlana A. Egorova
    Zuridin S. Nurmatov
    Anzhelika M. Milichkina
    Gulmira S. Suranbaeva
    Tatiana E. Kuchuk
    Irina V. Khamitova
    Elena V. Zueva
    Valery A. Ivanov
    Zhanylai N. Nuridinova
    Aisuluu A. Derkenbaeva
    Victoria G. Drobyshevskaya
    Gulsun Z. Sattarova
    Marat T. Kaliev
    Alexandra V. Gubanova
    Oyuna B. Zhimbaeva
    Alexandra P. Razumovskaya
    Vyacheslav N. Verbov
    Ivan V. Likhachev
    Alexey V. Krasnov
    Areg A. Totolian
    Medical Microbiology and Immunology, 2022, 211 : 195 - 210
  • [2] SARS-CoV-2 herd immunity of the Kyrgyz population in 2021
    Popova, Anna Y.
    Kasymov, Omor T.
    Smolenski, Vyacheslav Y.
    Smirnov, Vyacheslav S.
    Egorova, Svetlana A.
    Nurmatov, Zuridin S.
    Milichkina, Anzhelika M.
    Suranbaeva, Gulmira S.
    Kuchuk, Tatiana E.
    Khamitova, Irina, V
    Zueva, Elena, V
    Ivanov, Valery A.
    Nuridinova, Zhanylai N.
    Derkenbaeva, Aisuluu A.
    Drobyshevskaya, Victoria G.
    Sattarova, Gulsun Z.
    Kaliev, Marat T.
    Gubanova, Alexandra, V
    Zhimbaeva, Oyuna B.
    Razumovskaya, Alexandra P.
    Verbov, Vyacheslav N.
    Likhachev, Ivan, V
    Krasnov, Alexey, V
    Totolian, Areg A.
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2022, 211 (04) : 195 - 210
  • [3] Presumed population immunity to SARS-CoV-2 in South Korea, April 2022
    Jang, Eun Jung
    Choe, Young June
    Choe, Seung Ah
    Kim, Yoo-Yeon
    Kim, Ryu Kyung
    Kim, Jia
    Lim, Do Sang
    Lee, Ju Hee
    Yi, Seonju
    Lee, Sangwon
    Park, Young-Joon
    OSONG PUBLIC HEALTH AND RESEARCH PERSPECTIVES, 2022, 13 (05) : 377 - 381
  • [4] Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021
    Tunheim, Gro
    Ro, Gunnar Oyvind Isaksson
    Chopra, Adity
    Aase, Audun
    Kran, Anne-Marte Bakken
    Vaage, John Torgils
    Lund-Johansen, Fridtjof
    Hungnes, Olav
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2022, 16 (06) : 1004 - 1013
  • [5] A framework for monitoring population immunity to SARS-CoV-2
    Lopman, Benjamin A.
    Shioda, Kayoko
    Nguyen, Quan
    Beckett, Stephen J.
    Siegler, Aaron J.
    Sullivan, Patrick S.
    Weitz, Joshua S.
    ANNALS OF EPIDEMIOLOGY, 2021, 63 : 75 - 78
  • [6] Estimates of SARS-CoV-2 Hospitalization and Fatality Rates in the Prevaccination Period, United States
    Griffin, Isabel
    King, Jessica
    Lyons, B. Casey
    Singleton, Alyson L.
    Deng, Xidong
    Bruce, Beau B.
    Griffin, Patricia M.
    EMERGING INFECTIOUS DISEASES, 2024, 30 (06) : 1144 - 1153
  • [7] Immunity Against SARS-CoV-2 in the German Population
    Schulze-Wundling, Kai
    Ottensmeyer, Patrick Frank
    Meyer-Schlinkmann, Kristin Maria
    Deckena, Marek
    Krueger, Stefan
    Schlinkert, Simon
    Budde, Axel
    Muenstermann, Dieter
    Toepfner, Nicole
    Petersmann, Astrid
    Nauck, Matthias
    Karch, Andre
    Lange, Berit
    Blaschke, Sabine
    Tiemann, Carsten
    Streeck, Hendrik
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2023, 120 (19): : 337 - +
  • [8] SARS-CoV-2 immunity
    Antonio Bertoletti
    Cellular & Molecular Immunology, 2024, 21 : 101 - 102
  • [9] SARS-CoV-2 immunity
    Bertoletti, Antonio
    CELLULAR & MOLECULAR IMMUNOLOGY, 2024, 21 (02) : 101 - 102
  • [10] SARS-CoV-2 Reinfection With Different SARS-CoV-2 Variants in Children, Ohio, United States
    Wang, Huanyu
    Wright, Tori
    Everhart, Kathy
    Oyeniran, Sophonie J.
    Mejias, Asuncion
    Leber, Amy L.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2023, 12 (04) : 198 - 204